Lonza Group has been granted a patent for a recombinant host cell that reduces the expression of an endogenous FLO8 protein. The host cell contains a heterologous expression cassette with a gene of interest under the control of a repressible expression cassette promoter. This invention allows for the production of a protein of interest using the recombinant host cell. GlobalData’s report on Lonza Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Lonza Group, Nanoemulsion cosmetics was a key innovation area identified from patents. Lonza Group's grant share as of September 2023 was 58%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for a recombinant host cell with reduced flo8 protein expression
A recently granted patent (Publication Number: US11773424B2) describes a recombinant host cell and methods for increasing the yield of a protein of interest (POI) produced by the cell. The host cell is engineered to reduce the expression of an endogenous FLO8 protein compared to a wild-type host cell. This is achieved by introducing a heterologous expression cassette containing a gene of interest (GOI) under the control of a repressible expression cassette promoter (ECP). The ECP can be repressed by a non-methanol carbon source.
The patent claims also describe methods for producing the POI using the recombinant host cell. The methods involve culturing the host cell under conditions that promote the production of the POI. The ECP can be induced in the presence of a growth-limiting amount of a non-methanol carbon source and repressed in the presence of an excess amount of the carbon source. The methods can be performed in a batch phase or a fed-batch/continuous cultivation phase.
The patent claims further specify that the expression cassette may include a nucleotide sequence encoding a signal peptide, which enables the secretion of the POI. The GOI can encode various types of proteins, including antigen-binding proteins, therapeutic proteins, enzymes, peptides, protein antibiotics, toxin fusion proteins, carbohydrate-protein conjugates, structural proteins, regulatory proteins, vaccine antigens, growth factors, hormones, cytokines, process enzymes, and metabolic enzymes.
The recombinant host cell described in the patent claims can be either Komagataella phaffii or Komagataella pastoris. The ECP in the host cell can have at least 85%, 90%, or 95% sequence identity to a region of at least 300 nucleotides, including the 3' end of specific sequences provided in the claims.
Overall, this patent provides a novel approach for increasing the yield of a protein of interest by reducing the expression of an endogenous gene and utilizing a repressible expression cassette promoter. The methods described in the patent claims offer potential applications in various fields, including biotechnology, pharmaceuticals, and industrial protein production.
To know more about GlobalData’s detailed insights on Lonza Group, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
